Immune responses to tuberculosis in developing countries: implications for new vaccines
- PMID: 16056257
- DOI: 10.1038/nri1666
Immune responses to tuberculosis in developing countries: implications for new vaccines
Abstract
Tuberculosis is out of control in developing countries, where it is killing millions of people every year. In these areas, the present vaccine - Mycobacterium bovis bacillus Calmette-Guérin (BCG) - is failing. Progressive tuberculosis occurs because the potentially protective T helper 1 (T(H)1)-cell response is converted to an immunopathological response that fails to eliminate the bacteria. Here, we discuss the data indicating that the problem in developing countries is not a lack of adequate T(H)1-cell responses but, instead, an exaggerated tendency to switch to immunopathological responses. We propose that a successful vaccine needs to block this immunopathology, because it is not the quantity of T(H)1-cell activity that matters but, rather, its context.
Similar articles
-
Immune systems in developed and developing countries; implications for the design of vaccines that will work where BCG does not.Tuberculosis (Edinb). 2006 May-Jul;86(3-4):152-62. doi: 10.1016/j.tube.2006.01.018. Epub 2006 Feb 28. Tuberculosis (Edinb). 2006. PMID: 16510309 Review.
-
Therapeutic efficacy of a tuberculosis DNA vaccine encoding heat shock protein 65 of Mycobacterium tuberculosis and the human interleukin 2 fusion gene.Tuberculosis (Edinb). 2009 Jan;89(1):54-61. doi: 10.1016/j.tube.2008.09.005. Epub 2008 Dec 3. Tuberculosis (Edinb). 2009. PMID: 19056317
-
Do successful tuberculosis vaccines need to be immunoregulatory rather than merely Th1-boosting?Vaccine. 2005 Mar 18;23(17-18):2115-20. doi: 10.1016/j.vaccine.2005.01.069. Vaccine. 2005. PMID: 15755581 Review.
-
Efficacy of recombinant bacille Calmette-Guérin vaccine secreting interleukin-15/antigen 85B fusion protein in providing protection against Mycobacterium tuberculosis.J Infect Dis. 2008 May 1;197(9):1263-74. doi: 10.1086/586902. J Infect Dis. 2008. PMID: 18422438
-
Enhanced immunoprotective potential of Mycobacterium tuberculosis Ag85 complex protein based vaccine against airway Mycobacterium tuberculosis challenge following intranasal administration.FEMS Immunol Med Microbiol. 2006 Jul;47(2):233-41. doi: 10.1111/j.1574-695X.2006.00087.x. FEMS Immunol Med Microbiol. 2006. PMID: 16831210
Cited by
-
Immunoproteomic identification of human T cell antigens of Mycobacterium tuberculosis that differentiate healthy contacts from tuberculosis patients.Mol Cell Proteomics. 2010 Mar;9(3):538-49. doi: 10.1074/mcp.M900299-MCP200. Epub 2009 Dec 22. Mol Cell Proteomics. 2010. PMID: 20031926 Free PMC article.
-
The immunology of tuberculosis: from bench to bedside.Respirology. 2010 Apr;15(3):433-50. doi: 10.1111/j.1440-1843.2010.01739.x. Respirology. 2010. PMID: 20415982 Free PMC article. Review.
-
Significance of the Differential Peptidome in Multidrug-Resistant Tuberculosis.Biomed Res Int. 2019 Jan 17;2019:5653424. doi: 10.1155/2019/5653424. eCollection 2019. Biomed Res Int. 2019. PMID: 30792993 Free PMC article.
-
Human lung immunity against Mycobacterium tuberculosis: insights into pathogenesis and protection.Am J Respir Crit Care Med. 2011 Mar 15;183(6):696-707. doi: 10.1164/rccm.201006-0963PP. Epub 2010 Nov 12. Am J Respir Crit Care Med. 2011. PMID: 21075901 Free PMC article.
-
Gene expression and cytokine profile correlate with mycobacterial growth in a human BCG challenge model.J Infect Dis. 2015 May 1;211(9):1499-509. doi: 10.1093/infdis/jiu615. Epub 2014 Nov 7. J Infect Dis. 2015. PMID: 25381367 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical